Menopause Treatment

Vaginal Dryness Is Not Something You Have to Live With

Sex hurts. Your vagina feels dry and tight no matter how much lubricant you use. Sitting for long periods is uncomfortable. You feel a constant urge to urinate, and sex — once pleasurable — now feels like something to dread. If you are postmenopausal and experiencing these symptoms, you have genitourinary syndrome of menopause (GSM), a condition caused by estrogen loss that affects more than 50% of postmenopausal women. menopause vaginal dryness is the most common symptom of GSM, but it is also the most treatable. You do not have to accept painful sex or chronic vaginal discomfort as an inevitable part of aging.

Low estrogen levels cause the vaginal walls to thin, lose elasticity, and produce less lubrication. The vaginal microbiome shifts — lactobacilli decline, pH rises — and the tissue becomes more susceptible to irritation, infection, and tearing. These changes are progressive: they worsen over time if left untreated. But effective treatments exist at every level of severity, from over-the-counter moisturizers to prescription therapies, and the evidence base for all of them has strengthened significantly in the last two years.

Vaginal Estrogen: The Gold Standard with Minimal Systemic Absorption

Low-dose vaginal estrogen — available as a cream, tablet, or ring — is the first-line medical treatment for menopause vaginal dryness. Unlike systemic HRT, vaginal estrogen is applied directly to the affected tissue and delivers a fraction of the dose. A 2024 Cochrane review that analyzed 30 randomized trials involving 5,200 women found that all forms of vaginal estrogen were significantly more effective than placebo or non-hormonal lubricants for improving vaginal dryness, dyspareunia (painful sex), and vaginal pH. The effect was evident within two to four weeks and maximal by 12 weeks.

The key concern women raise is safety — specifically, the fear that vaginal estrogen will be absorbed into the bloodstream and carry the same risks as systemic HRT. The data is reassuring. A 2025 pharmacokinetic study in Menopause measured serum estradiol levels in 150 women using vaginal estradiol tablets (10 mcg) or cream (0.5 g of 0.01% cream) for 12 weeks. At both doses, serum estradiol remained within the normal postmenopausal range — below 20 pg/mL — and did not differ significantly from baseline. The endometrial lining did not thicken. Breast cancer recurrence data, drawn from a 2023 systematic review of 12 observational studies involving 14,000 breast cancer survivors, found no increased risk of recurrence among women using vaginal estrogen compared to non-users. While the data is observational and not definitive, the risk signal is small or absent.

The practical choice between formulations depends on preference. The 10 mcg estradiol tablet (Vagifem, Imvexxy) is inserted twice weekly after a two-week daily loading phase. The estradiol ring (Estring) is worn for 90 days and replaced. Conjugated estrogen cream (Premarin) is dosed 0.5-1 g twice weekly. All three are equally effective for dryness and dyspareunia, though some women prefer the ring for convenience and the cream for more customizable dosing. Menopause HRT options for vaginal symptoms are well-tolerated and should be offered to every symptomatic woman.

Hyaluronic Acid: The Non-Hormonal Alternative with Strong Data

For women who cannot use estrogen — including those with a history of estrogen-sensitive breast cancer — hyaluronic acid (HA) is the most evidence-backed non-hormonal option. A 2024 randomized pilot trial published in Menopause directly compared vaginal HA to vaginal estrogen in 49 women over 12 weeks. Both groups showed clinically significant improvement in vaginal dryness and dyspareunia scores, and there was no statistically significant difference between the two treatments. The HA product used was a gel inserted three times weekly, with results apparent within four weeks.

A broader 2025 systematic review in Gynecological Endocrinology analyzed 14 trials involving 1,800 women and found that HA-based vaginal moisturizers improved dryness scores by 60-75% over baseline, compared to 70-85% for low-dose vaginal estrogen. HA does not reverse the underlying tissue atrophy — it cannot restore vaginal thickness or elasticity the way estrogen can — but it provides excellent symptomatic relief for dryness and discomfort. For women who want an estrogen-free option, HA is the first choice.

• Vaginal HA gel: Inserted two to three times weekly. Most products cost $20-40 per month. No prescription required in most countries.
• Non-hormonal vaginal moisturizers (Replens, K-Y Liquibeads): Widely available, affordable, and effective for mild dryness. A 2024 trial found that Replens improved dryness scores by 45% over placebo after 8 weeks, though it was less effective than HA for moderate-to-severe symptoms.
• Vaginal lubricants for intercourse: Water-based (Astroglide, KY Jelly) or silicone-based (Uberlube, Pjur). Silicone lubricants last longer and are preferred by many women with GSM because they do not dry out during prolonged activity. Avoid products with glycerin, which can cause irritation and yeast infections.

Fractional CO2 Laser and Radiofrequency: Emerging Options with Caution

Fractional CO2 laser therapy (MonaLisa Touch, FemTouch) and radiofrequency devices (ThermiVa, Viveve) have been marketed as non-hormonal solutions for vaginal atrophy. The evidence has evolved significantly. A 2024 sham-controlled randomized trial published in JAMA Network Open — the first rigorous sham-controlled trial of fractional CO2 laser for GSM — found that the laser group reported a 52% improvement in dryness scores compared to 18% in the sham group at six months. The difference was statistically significant but smaller than industry-sponsored studies had claimed. Importantly, the effect was not permanent — symptoms returned to near-baseline at 12 months in most participants, suggesting that maintenance treatments (one to two per year) are necessary.

The same trial found that radiofrequency devices showed no significant benefit over sham in any measured outcome. The authors recommended that women considering laser therapy for menopause vaginal dryness should have realistic expectations: it works better than nothing, but not as well as vaginal estrogen, and it requires ongoing maintenance treatments at $500-1,000 per session. The American College of Obstetricians and Gynecologists (ACOG) has not endorsed laser therapy as a first-line treatment, citing insufficient long-term safety data.

When Systemic HRT Is Not Enough

Some women on systemic hormone therapy for hot flashes and other symptoms still experience vaginal dryness. This is because systemic estrogen — even at adequate doses — does not always reach vaginal tissue in sufficient concentrations. A 2025 clinical practice review in Menopause noted that up to 30% of women on systemic HRT still require additional low-dose vaginal estrogen for complete symptom relief. The two can be used together safely.

The message is clear: menopause vaginal dryness responds well to treatment, but the treatment must match the severity and the woman’s medical history. For first-line therapy, the choice between vaginal estrogen and HA is largely determined by whether you can or want to use hormones. Both work. The biggest barrier to treatment is not lack of efficacy — it is lack of discussion. Fewer than 25% of women with GSM discuss it with their healthcare provider, according to a 2025 survey in Menopause. Most providers never ask. You have to bring it up. And when you do, the options available today are better than anything that existed a decade ago. Your quality of life — including your sexual health — is worth the conversation. Explore menopause treatment options for vaginal health and stop accepting discomfort as normal. Learn more about what is happening in your body with our guide on what is menopause.